 AUSTIN, Texas, July 27, 2022 GLOBE NEWSWIRE -- Plus Therapeutics, Inc. Nasdaq: PSTV the Company, a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Norman LaFrance, M.D., Chief Medical Officer and SVP will give a presentation on the Companys lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome 186RNL, and share updates on the U.S. ReSPECT clinical trials at the inaugural Targeted Radiopharmaceuticals Summit, organized by Hanson Wade, being held July 26-28, 2022 at the Boston Park Plaza in Boston, Massachusetts. 